Shandong Provincial Hospital

Haematology

Established in 1962, the Hematology Department of Shandong Provincial Hospital is the Shandong branch of the national clinical research center for blood diseases, an initial pilot unit for standardized lymphoma quality control, an accredited Chinese chronic lymphocytic leukemia center of excellence, a provincial key clinical specialty, a China Marrow Donor Program hematopoietic stem-cell transplantation and designated collection unit, and a Taishan Scholar post. It hosts the provincial lymphoma engineering research center, hematology key laboratory and lymphoma big-data innovation alliance, and is a provincial distinguished clinical specialty, a national Women's Civilization post, an accredited drug clinical trial institution and a doctoral and postdoctoral training site for Shandong University and Shandong First Medical University. Its central and Olympic Sports campuses have two wards and 104 medical and nursing staff, including 37 medical team members, 14 of senior rank and two doctoral supervisors. Talent includes one national-level expert, one Taishan distinguished expert, one provincial outstanding young expert, three Taishan young experts and provincial-level health leaders and university innovation team leaders. Members hold provincial hematology and diagnostics society chair positions and international journal editorial roles. The department provides standardized care from routine diagnosis to hematopoietic stem-cell transplantation and cellular immunotherapy. Its six subspecialties are stem-cell transplantation, lymphoma and myeloma, leukemia, myeloproliferative disease, red-cell disease, and bleeding and coagulation disorders. Dedicated outpatient services include multidisciplinary clinics for adult lymphadenopathy and abnormal globulins and a cellular therapy clinic. It performs allogeneic, autologous, microtransplantation and cord-blood transplantation, with experience optimizing conditioning and preventing and treating graft-versus-host disease; it is a provincial standardized clinical technology training base. The provincial distinguished lymphoma specialty has an MDT, established the provincial lymphoma big-data alliance and uses prognostic stratification, individualized care and cellular immunotherapies such as CAR-T for relapsed or refractory blood diseases. The hospital reports over 30 national research projects, over 300 SCI-indexed papers, nine granted national invention patents and participation in over 20 clinical guidelines or expert consensuses. Awards include the first Shandong science and technology progress prize, Huayi youth medical science and technology prize, second Shandong natural science prize and special Shandong medical science and technology prize. Research has been cited in international guidelines and presented at American and European hematology annual meetings over multiple years. The department also holds public education and free consultation events for people with blood disorders.